Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?

Shenmiao Yang, Neil E. Kay, Min Shi, Curtis A. Hanson, Robert Peter Gale

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)2743-2747
Number of pages5
Issue number11
StatePublished - Nov 2022

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this